All In Biotech

Free tool

FAERS Monitor: Loqtorzi

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761240 or its brand name (Loqtorzi, Toripalimab-Tpzi). Reports on generic versions are filed under their own applications.

Reports

43

Serious

20

47% of reports

Hospitalization

8

Death reported

12

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use25
  • death6
  • neutropenia4
  • fatigue3
  • hospitalisation3
  • pneumonitis aspiration3
  • respiratory distress3
  • autoimmune myositis2
  • abdominal pain1
  • acute kidney injury1
  • adverse drug reaction1
  • blood calcium abnormal1
  • blood pressure decreased1
  • breast cancer metastatic1
  • condition aggravated1

Reports by year received

View as table
YearReports
20244
20253
202636

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,116 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
pneumonitis aspirationSignal34333.01447.38,943
autoimmune myositis22083.5536.72,331
blood calcium abnormal1294.442.473
respiratory distressSignal353.217.9106
breast cancer metastatic145.66.610
neutropeniaSignal414.45.738
off label useSignal2514.010.8301
hospitalisationSignal39.63.215
blood pressure decreased17.41.11
adverse drug reaction15.40.81
deathSignal63.41.68
acute kidney injury13.20.50
abdominal pain12.10.30
fatigue31.90.61
condition aggravated11.60.20

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.